Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours

Basic and Clinical Pharmacology and Toxicology

Volumn 105, Issue 5, 2009, Pages 333-338

  Roohbakhsh, Ali ^a   Keshavarz, Samaneh ^a   Hasanein, Parisa ^b   Rezvani, Mohammad Ebrahim ^a   Moghaddam, Akbar Hajizadeh ^c  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BU ALI SINA UNIVERSITY   (Iran)

^c UNIVERSITY OF MAZANDARAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; BICUCULLINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOCANNABINOID; PHACLOFEN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; GABAERGIC SYSTEM; HIPPOCAMPUS; MALE; MAZE TEST; MODULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMIDOHYDROLASES; ANIMALS; ANXIETY; BACLOFEN; BEHAVIOR, ANIMAL; BENZAMIDES; BICUCULLINE; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; GABA ANTAGONISTS; HIPPOCAMPUS; MALE; MAZE LEARNING; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1;

RATTUS;

EID: 70350025072     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2009.00449.x     Document Type: Article

References (44)

1. Chaperon F, Thiebot MH. Behavioral effects of cannabinoid agents in animals. Critical Rev Neurobiol 1999 13 : 243 281.
2. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoids receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991 11 : 563 583.
3. Rodríguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF et al. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 1996 276 : 56 64.
4. Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 2001 70 : 123 131.
5. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP55,940 in the social interaction test. Pharmacol Biochem Behav 2004 77 : 567 573.
6. Rutkowska M, Jamontt J, Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep 2006 58 : 200 206.
7. Rubino T, Guidali C, Vigano D, Realini N, Valenti M, Massi P et al. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour. Neuropharmacology 2008 54 : 151 160.
8. Carlini EA. The good and the bad effects of (-) trans-delta-9- tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon 2004 44 : 461 467.
9. Gourlay D. Addiction and pain medicine. Pain Res Manag 2005 10 (Suppl A 38A 43A.
10. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003 4 : 873 884.
11. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005 74 : 411 432.
12. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003 9 : 76 81.
13. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ et al. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 2006 148 : 102 113.
14. Varvel SA, Wise LE, Niyuhire F, Cravatt BF, Lichtman AH. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007 32 : 1032 1041.
15. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007 62 : 1103 1110.
16. Ognibene E, Adriani W, Laviola G. Anxiolytic and reward-related properties of URB597, a novel FAAH inhibitor, in CD1 mice. Eur Neuropsychopharmacol 2006 16 : S460.
17. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006 318 : 304 311.
18. Tsou K, Nogueron MI, Muthian S, Sanudo-Pena MC, Hillard CJ, Deutsch DG et al. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci Lett 1998 254 : 137 140.
19. Egertová M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 1998 265 : 2081 2085.
20. Roy-Byrne PP. The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. J Clin Psychiatry 2005 66 : 14 20.
21. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003 83 : 1017 1066.
22. Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 2003 9 : 474 478.
23. Rahminiwati M, Nishimura M. Effects of delta 9-tetrahydrocannabinol and diazepam on feeding behavior in mice. J Vet Med Sci 1999 61 : 351 355.
24. Haller J, Mátyás F, Soproni K, Varga B, Barsy B, Németh B et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007 25 : 2445 2456.
25. Triet D, Degroot A. Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shoke-probe tests. Brain Res 2002 949 : 60 70.
26. File SE, Cheeta S, Kenny PJ. Neurobiological mechanisms by which nicotine mediates different types of anxiety. Eur J Pharmacol 2000 393 : 231 236.
27. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press, San Diego, 1998.
28. Rezayat M, Roohbakhsh A, Zarrindast MR, Massoudi R, Djahanguiri B. Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol Behav 2005 84 : 775 782.
29. Roohbakhsh A, Moghaddam AH, Massoudi R, Zarrindast MR. Role of dorsal hippocampal cannabinoid receptors and nitric oxide in anxiety like behaviours in rats using the elevated plus-maze test. Clin Exp Pharmacol Physiol 2007 34 : 223 229.
30. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 2008 18 : 1292 1301.
31. Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 1986 24 : 525 529. (Pubitemid 16145187)
32. Rodgers RJ, Johnson NJT. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 1995 52 : 297 303.
33. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 2004 145 : 5431 5438.
34. Moise AM, Eisenstein SA, Astarita G, Piomelli D, Hohmann AG. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology 2008 200 : 333 346.
35. Murillo-Rodríguez E, Vázquez E, Millán-Aldaco D, Palomero-Rivero M, Drucker-Colin R. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur J Pharmacol 2007 562 : 82 91.
36. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F et al. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 2007 27 : 832 839.
37. Sütt S, Raud S, Areda T, Reimets A, Kõks S, Vasar E. Cat odour-induced anxiety-a study of the involvement of the endocannabinoid system. Psychopharmacology 2008 198 : 509 520.
38. Sulcova A, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998 59 : 347 352.
39. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 2007 192 : 61 70.
40. Navarro M, Hernandez E, Munoz RM, del Arco R, Villanua MA, Carrera MRA et al. Acute administration of CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 1997 8 : 491 496.
41. Akinshola BE, Chakrabarti A, Onaivi ES. In vitro and in vivo action of cannabinoids. Neurochem Res 1999 24 : 1233 1240.
42. Haller J, Bakos N, Szimay M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002 16 : 1395 1398.
43. Moreira FA, Aguiar DC, Guimarães FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 2007 52 : 958 965.
44. Naderi N, Haghparast A, Saber-Tehrani A, Rezaii N, Alizadeh AM, Khani A et al. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol Biochem Behav 2008 89 : 64 75.